5th Edition of International Heart Congress
June 24-26, 2027 | Hybrid Event
Valvular Heart Disease
Valvular heart disease occurs when one or more of the heart's valves are damaged, affecting the normal flow of blood through the heart. This condition can involve valve stenosis (narrowing of the valve opening) or valve regurgitation (leakage of the valve), both of which can impair heart function over time. Common causes include age-related changes, infections like endocarditis, or congenital defects. Symptoms of valvular heart disease may include fatigue, shortness of breath, and swelling in the legs. Treatment options vary based on the severity of the condition and may include medications to control symptoms or surgical interventions such as valve repair or replacement. Early detection and management are key to preventing more severe complications.
John R Doty
Intermountain Medical Center, United States
Trevor Tucker
Dynamic Vascular Resolution Inc., Canada
Thomas J Webster
Brown University, United States
Uwe Peter Tigor
Auxilius Pharma, United States
Fatima Michelle Villa Jimenez
Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico
Mancilla Sandoval Yoana Tenneth
Instituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas", Mexico
Sergey Suchkov
N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian FederationSubmit your abstract Today
Title : Healing a broken heart: One nano beat at a time
Thomas J Webster, Brown University, United States
Title : Surgical options for aortic valve preservation
John R Doty, Intermountain Medical Center, United States
Title : Revolutionizing heart health through Personalized & Precision Medicine (PPM): Towards personalized cardiovascular prevention, precision cardiac care & rehabilitation via optimizing Cardiac Hospital Networks
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibody-proteases as unique biomarkers, potential targets and translational tools of the next step generation to be used in personalized and precision cardiology practice
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Investigation of bergapten’s pharmacological activity against doxorubicin induced cardiotoxicity: supporting evidence from cellular and animal models
Bijoy Krishna Banik, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, India
Title : Frequency of residual risk in cardiovascular secondary prevention in patients treated at the Reina Fabiola University Clinic
Agustin Joison, Cordoba Catholic University, Argentina